| 產品編號 | bs-1223R-BF350 |
| 英文名稱1 | Rabbit Anti-Aggrecan1/BF350 Conjugated antibody |
| 中文名稱 | BF350標記的軟骨蛋白聚糖抗體 |
| 別 名 | PGCA_HUMAN; ACAN; AGC 1; AGC1; AGCAN; Aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal A0122); Aggrecan 1; Aggrecan core protein; Aggrecan proteoglycan; Aggrecan structural proteoglycan of cartilage; Aggrecan1; ATEGQV; Aggrecan ARGxx; Cartilage specific proteoglycan core protein; Chondroitin sulfate proteoglycan 1 ; Chondroitin sulfate proteoglycan 1 large aggregating proteoglycan antigen identified by monoclonal antibody A0122; Chondroitin sulfate proteoglycan core protein 1; CSPG 1; CSPG1; CSPGCP; JSCATE; Large aggregating proteoglycan; MSK 16; MSK16; SEDK. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 免疫學 信號轉導 干細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Mouse, Rat, (predicted: Human, Chicken, Dog, Pig, Cow, Horse, Rabbit, ) |
| 產品應用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 208/248kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Aggrecan |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: Aggrecan is a member of a family of large, aggregating proteoglycans (also including versican, brevican and neurocan) which is found in articular cartilage. Aggrecan is composed of three major domains: G1, G2, and G3. Between the G1 and G2 domains there is an interglobulin region (IGD). The IGD region is the major site of cleavage by specific proteases like metalloproteinases (MMPs) and aggrecanase. Aggrecan cleavage has been associated with a number of degenerative diseases including rheumatoid arthritis and osteoarthritis. There is evidence that this family of proteoglycans modulates cell adhesion, migration, and axonal outgrowth in the CNS. Function: Aggrecan has been detected in neural precursor cells (neurospheres; Kabos et al, 2004) During differentiation, neurospheres downregulate Chondroitin sulfate proteoglycans (CSPGs). Proliferating neural precursors synthesize lecticans, including aggrecan, which are downregulated with differentiation; suggesting a link between CSPGs and CNS precursor biology. Subunit: Interacts with FBLN1. Interacts with COMP. Subcellular Location: Secreted, extracellular space, extracellular matrix. Tissue Specificity: Restricted to cartilages. Post-translational modifications: Contains mostly chondroitin sulfate, but also keratan sulfate chains, N-linked and O-linked oligosaccharides. The release of aggrecan fragments from articular cartilage into the synovial fluid at all stages of human osteoarthritis is the result of cleavage by aggrecanase. DISEASE: Spondyloepiphyseal dysplasia type Kimberley (SEDK) [MIM:608361]: Spondyloepiphyseal dysplasias are a heterogeneous group of congenital chondrodysplasias that specifically affect epiphyses and vertebrae. The autosomal dominant SEDK is associated with premature degenerative arthropathy. Note=The disease is caused by mutations affecting the gene represented in this entry. Spondyloepimetaphyseal dysplasia aggrecan type (SEMD-ACAN) [MIM:612813]: A bone disease characterized by severe short stature, macrocephaly, severe midface hypoplasia, short neck, barrel chest and brachydactyly. The radiological findings comprise long bones with generalized irregular epiphyses with widened metaphyses, especially at the knees, platyspondyly, and multiple cervical-vertebral clefts. Note=The disease is caused by mutations affecting the gene represented in this entry. Osteochondritis dissecans short stature and early-onset osteoarthritis (OD) [MIM:165800]: A type of osteochondritis defined as a separation of cartilage and subchondral bone from the surrounding tissue, primarily affecting the knee, ankle and elbow joints. It is clinically characterized by multiple osteochondritic lesions in knees and/or hips and/or elbows, disproportionate short stature and early-onset osteoarthritis. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the aggrecan/versican proteoglycan family. Contains 1 C-type lectin domain. Contains 1 EGF-like domain. Contains 1 Ig-like V-type (immunoglobulin-like) domain. Contains 4 Link domains. Contains 1 Sushi (CCP/SCR) domain. Database links: Entrez Gene: 176 Human Entrez Gene: 11595 Mouse Omim: 155760 Human SwissProt: P16112 Human SwissProt: Q61282 Mouse Unigene: 2159 Human Unigene: 358571 Mouse Unigene: 54503 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Aggrecan是軟骨細胞外基質的主要結構成分之一。它與膠原蛋白網絡結合，維持軟骨彈性、緩沖壓力，承擔負荷,并有自我潤滑的性能。蛋白多糖的進行性喪失是骨性關節病發病主要原因之一。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
